BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21645556)

  • 1. Δ(9)-THC and WIN55,212-2 affect brain tissue levels of excitatory amino acids in a phenotype-, compound-, dose-, and region-specific manner.
    Galanopoulos A; Polissidis A; Papadopoulou-Daifoti Z; Nomikos GG; Antoniou K
    Behav Brain Res; 2011 Oct; 224(1):65-72. PubMed ID: 21645556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individual differences in the effects of cannabinoids on motor activity, dopaminergic activity and DARPP-32 phosphorylation in distinct regions of the brain.
    Polissidis A; Chouliara O; Galanopoulos A; Rentesi G; Dosi M; Hyphantis T; Marselos M; Papadopoulou-Daifoti Z; Nomikos GG; Spyraki C; Tzavara ET; Antoniou K
    Int J Neuropsychopharmacol; 2010 Oct; 13(9):1175-91. PubMed ID: 19941698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
    Sim-Selley LJ; Martin BR
    J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of cannabinoid CB1 receptors and Gi/o protein activation in the modulation of synaptosomal Na+,K+-ATPase activity by WIN55,212-2 and delta(9)-THC.
    Araya KA; David Pessoa Mahana C; González LG
    Eur J Pharmacol; 2007 Oct; 572(1):32-9. PubMed ID: 17644088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta 9-tetrahydrocannabinol.
    Romero J; Berrendero F; García-Gil L; Ramos JA; Fernández-Ruiz JJ
    J Mol Neurosci; 1998 Oct; 11(2):109-19. PubMed ID: 10096037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cannabinoid CB1 receptor biphasically modulates motor activity and regulates dopamine and glutamate release region dependently.
    Polissidis A; Galanopoulos A; Naxakis G; Papahatjis D; Papadopoulou-Daifoti Z; Antoniou K
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):393-403. PubMed ID: 22391102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation.
    Hoffman AF; Oz M; Yang R; Lichtman AH; Lupica CR
    Learn Mem; 2007; 14(1-2):63-74. PubMed ID: 17202425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional tolerance and blockade of long-term depression at synapses in the nucleus accumbens after chronic cannabinoid exposure.
    Hoffman AF; Oz M; Caulder T; Lupica CR
    J Neurosci; 2003 Jun; 23(12):4815-20. PubMed ID: 12832502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effects of Delta(9)-tetrahydrocannabinol against N-methyl-d-aspartate-induced AF5 cell death.
    Chen J; Lee CT; Errico S; Deng X; Cadet JL; Freed WJ
    Brain Res Mol Brain Res; 2005 Apr; 134(2):215-25. PubMed ID: 15836919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intra-accumbal NMDA but not AMPA/kainate receptor antagonist attenuates WIN55,212-2 cannabinoid receptor agonist-induced antinociception in the basolateral amygdala in a rat model of acute pain.
    Ghalandari-Shamami M; Hassanpour-Ezatti M; Haghparast A
    Pharmacol Biochem Behav; 2011 Dec; 100(2):213-9. PubMed ID: 21924283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia.
    Suplita RL; Eisenstein SA; Neely MH; Moise AM; Hohmann AG
    Neuropharmacology; 2008 Jan; 54(1):161-71. PubMed ID: 17714742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoids inhibit excitatory inputs to neurons in the shell of the nucleus accumbens: an in vivo electrophysiological study.
    Pistis M; Muntoni AL; Pillolla G; Gessa GL
    Eur J Neurosci; 2002 Jun; 15(11):1795-802. PubMed ID: 12081659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoids induce latent sensitization in a preclinical model of medication overuse headache.
    Kopruszinski CM; Navratilova E; Vagnerova B; Swiokla J; Patwardhan A; Dodick D; Porreca F
    Cephalalgia; 2020 Jan; 40(1):68-78. PubMed ID: 31311288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-lasting alterations of hippocampal GABAergic neurotransmission in adult rats following perinatal Δ
    Beggiato S; Borelli AC; Tomasini MC; Morgano L; Antonelli T; Tanganelli S; Cuomo V; Ferraro L
    Neurobiol Learn Mem; 2017 Mar; 139():135-143. PubMed ID: 28104530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long lasting effects of chronic WIN55,212-2 treatment on mesostriatal dopaminergic and cannabinoid systems in the rat brain.
    Perdikaris P; Tsarouchi M; Fanarioti E; Natsaridis E; Mitsacos A; Giompres P
    Neuropharmacology; 2018 Feb; 129():1-15. PubMed ID: 29113897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.
    Darmani NA; Janoyan JJ; Crim J; Ramirez J
    Eur J Pharmacol; 2007 Jun; 563(1-3):187-96. PubMed ID: 17362921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoids inhibit sodium-dependent, high-affinity excitatory amino acid transport in cultured rat cortical astrocytes.
    Shivachar AC
    Biochem Pharmacol; 2007 Jun; 73(12):2004-11. PubMed ID: 17445778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delta(9)-Tetrahydrocannabinol-induced desensitization of cannabinoid-mediated inhibition of synaptic transmission between hippocampal neurons in culture.
    Lundberg DJ; Daniel AR; Thayer SA
    Neuropharmacology; 2005 Dec; 49(8):1170-7. PubMed ID: 16157354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs.
    Martin BR; Compton DR; Thomas BF; Prescott WR; Little PJ; Razdan RK; Johnson MR; Melvin LS; Mechoulam R; Ward SJ
    Pharmacol Biochem Behav; 1991 Nov; 40(3):471-8. PubMed ID: 1666911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
    Darmani NA; Sim-Selley LJ; Martin BR; Janoyan JJ; Crim JL; Parekh B; Breivogel CS
    Eur J Pharmacol; 2003 Jan; 459(1):83-95. PubMed ID: 12505537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.